{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:09:47Z","timestamp":1790730587594,"version":"4.1.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1080\/19420862.2020.1795492","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T14:07:55Z","timestamp":1596377275000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Development and validation of an LC-MS\/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab"],"prefix":"10.1080","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-7790","authenticated-orcid":false,"given":"Sandor","family":"Schokker","sequence":"first","affiliation":[{"name":"Cancer Center Amsterdam (CCA), Amsterdam University Medical Centers, University of Amsterdam","place":["Amsterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Fusetti","sequence":"additional","affiliation":[{"name":"QPS Netherlands BV","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bonardi","sequence":"additional","affiliation":[{"name":"QPS Netherlands BV","place":["Groningen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco J.","family":"Molenaar","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam (CCA), Amsterdam University Medical Centers, University of Amsterdam","place":["Amsterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers, University of Amsterdam","place":["Amsterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9709","authenticated-orcid":false,"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam (CCA), Amsterdam University Medical Centers, University of Amsterdam","place":["Amsterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.001"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.10.008"},{"key":"e_1_3_3_4_1","first-page":"37(15)","article-title":"Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement","author":"Godara A","year":"2019","unstructured":"Godara A, Siddiqui NS, Lee L, Toskic D, Fogaren T, Varga C, Comenzo R, et al. Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement. J Clin Oncol. 2019;37(15).","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1315406"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31891-8"},{"key":"e_1_3_3_7_1","first-page":"JCO1901814","article-title":"Phase II Feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study","author":"Stroes CI","year":"2019","unstructured":"Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof M, van der Woude SO, Bennink RJ, Math\u00f4t RA, Krishnadath KK, Punt CJ, Verhoeven RH, et al. Phase II Feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study. J Clin Oncol. 2019;38(5):4624\u201371. JCO1901814.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5675-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03826-1"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6852"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.237"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00545-16"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058917"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000016"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.12.044"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21111464"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.7898"},{"key":"e_1_3_3_18_1","first-page":"7","article-title":"Applications of targeted proteomics and mass spectrometry in trastuzumab pharmacokinetics assessments","volume":"1","author":"Baru R","year":"2017","unstructured":"Baru R. Applications of targeted proteomics and mass spectrometry in trastuzumab pharmacokinetics assessments. J Syst Biol Proteome Res. 2017;1:7\u20139.","journal-title":"J Syst Biol Proteome Res"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0196"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.14.142"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2018.02.040"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2019.03.033"},{"key":"e_1_3_3_23_1","unstructured":"PeptideMass https:\/\/web.expasy.org\/peptide_mass\/."},{"key":"e_1_3_3_24_1","unstructured":"BLAST https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi?PAGE=Proteins."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.69"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02821-x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1546"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113102"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2400-5"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.356"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2009.05.043"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5b04276"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M110.006593"},{"key":"e_1_3_3_34_1","volume-title":"Guidance for Industry: bioanalytical Method Validation","year":"2001","unstructured":"Guidance for Industry: bioanalytical Method Validation. Rockville (MD): U.S. Food and Drug Administration. 2001. http:\/\/www.labcompliance.de\/documents\/FDA\/FDA-Others\/Laboratory\/f-507-bioanalytical-4252fnl.pdf"},{"key":"e_1_3_3_35_1","volume-title":"Guidance for industry: bioanalytical method validation","year":"2018","unstructured":"Guidance for industry: bioanalytical method validation. Rockville (MD):U.S. Food and Drug Administration. 2018. https:\/\/www.fda.gov\/media\/70858\/download"},{"key":"e_1_3_3_36_1","unstructured":"Guideline on bioanalytical method validation. European Medicines Agency 2011 https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2020.1795492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:01:08Z","timestamp":1762430468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2020.1795492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1080\/19420862.2020.1795492"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2020.1795492","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1795492"}}